In recent decades, several new drugs of different therapeutic classes have been introduced into diabetes treatment, but the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors has increased substantially [6], possibly because of their favorable side effect profiles. This evidence concerns the gene SLC5A2 and diabetes mellitus.